HR Execs on the Move


 
Genexa is the world`s first and only clean medicine company and was recognized in 2022 by Fast Company as the no. 1 Most Innovative Company in Wellness. We were founded in 2016 by two dads who believed medicine should only have the active ingredients you need, and not the artificial fillers you don`t. It`s medicine made clean, because that`s what people deserve. Our headquarters is located in Atlanta, where we strive to put people over everything
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.genexa.com
  • 1510 Ellsworth Industrial Boulevard NW Building Two, Suite 10
    Atlanta, GA USA 30318
  • Phone: 855.436.3921

Executives

Name Title Contact Details
Emily Culp
Chief Marketing Officer Profile

Similar Companies

Pediapharm

Pediapharm Inc. is a Verdun, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Afecta Pharmaceuticals

Afecta Pharmaceuticals is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Xerimis Inc

Xerimis Inc is a Moorestown, NJ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

BIOSAFE Inc

BIOSAFE Inc is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Neurogastrx

We are a specialty pharmaceutical company developing transformative therapies to advance the treatment of gastrointestinal (GI) disorders. We focus on developing treatments for GI disorders for which meaningful therapeutic innovation is required to satisfy unmet patient need and disease burden. Our management team and board of directors are comprised of professionals with extensive backgrounds in drug research and development, commercialization, finance and business development for leading global pharmaceutical companies and growth-stage biopharmaceutical companies. Our scientific advisory board consists of well-known gastroenterologists and clinical thought leaders. Today, our pipeline consists of two unique clinical stage therapies with the potential to bring benefit to millions of patients with chronic and debilitating GI disorders that are not adequately controlled.